A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer

Ann M. Mauer, Ezra E.W. Cohen, C. Patrick, +6

Journal of Thoracic Oncology

MedicinePathologyPhase Ii StudyBronchial NeoplasmCancer Treatment +4

The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study

Kenneth R. Hande, A. Hagey, Jordan Berlin, +7

Clinical Cancer Research

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Karen Yee, A. Hagey, Srđan Verstovšek, +17

Clinical Cancer Research

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

Elizabeth Fox, John M. Maris, Brigitte C. Widemann, +11

Clinical Cancer Research

A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients

Tian Ma, Alexander D. Fuld, James R. Rigas, +4

Chemotherapy

A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors

Elizabeth Fox, John M. Maris, Brigitte C. Widemann, +10

Clinical Cancer Research

Solid TumorsPharmacotherapyRefractory Solid TumorsHigh-grade GliomasGlioma +17

Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function

Agop Y. Bedikian, Jeffrey A. Silverman, Nicholas E. Papadopoulos, +7

The Journal of Clinical Pharmacology

ImmunologyVincristine SulfatePharmacotherapyCancer PatientsAdequate Liver Function +14

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Refractory or Relapsed Lymphoid Malignancies.

Wyndham H. Wilson, Anil Tulpule, Alexandra M. Levine, +10

Blood

Increasing diversity in pediatric hematology/oncology

Ernest Frugé, Joan M. Lakoski, Naomi L.C. Luban, +8

Pediatric Blood & Cancer